Transport of amino acids in muscle, gut and liver: relevance to metabolic control

Role of membrane transport in the regulation of skeletal muscle glutamine turnover

This paper reviews present understanding of the role played by the sarcolemmal glutamine transporter, system N(m), in control of intramuscular glutamine concentration. Glutamine transport in skeletal muscle is a saturable, stereospecific, Na dependent and insulin sensitive process. The activity of system N(m) is subject to modification during muscle denervation, diabetes and exposure to bacterial products in a manner consistent with the observed negative glutamine balance exhibited by muscle during such circumstances. The modification in transporter activity appears to be dependent on factors influencing the distribution of Na across the sarcolemma, the resting membrane potential and the active carrier population in the sarcolemma (possibly through up or down regulation of the number of transporter molecules). Derangements in net membrane glutamine transport during pathophysiological conditions may help, partly, to account for the loss in muscle glutamine which in turn may influence control of protein and carbohydrate metabolism in muscle. The free intramuscular glutamine concentration appears to act as a positive signal in the control of muscle protein turnover and glycogen synthesis, a finding that may have important therapeutic implications for limiting muscle wasting. The kinetic properties of the glutamine transporter and the dipeptidase activity in the muscle vascular bed allow the intramuscular glutamine pool to be repleted following administration of glutamine dipeptides (such as Ala-Gln) with the result that a net anabolic shift in protein balance and an amelioration in muscle glutamine efflux takes place.

Responses of glutamine transport in cultured rat skeletal muscle to osmotically induced changes in cell volume

1. In order to investigate the relationship between cellular hydration state and the rate of glutamine transport, tracer glutamine uptake into primary rat myotubes was studied at external osmolalities of 170, 320 or 430 mosmol kg-1. 2. Incubation of myotubes with glutamine (2 mM; 30 min) at 320 mosmol kg-1 increased cell volume and glutamine transport (by 35 and 36%, respectively); insulin (66 nM; 30 min) also increased cell volume and glutamine transport (by 22 and 40%, respectively) and the effects of insulin and glutamine combined were additive. The increase in glutamine uptake following glutamine pre-incubation represented an increase in Vmax of Na(+)-dependent glutamine transport. 3. There was an inverse relationship between myotube glutamine transport and external osmolality after 30 min exposure. 4. During hyposmotic (170 mosmol kg-1) exposure there were large, rapid increases of cell volume and glutamine transport; the latter increased transiently (during the cell swelling phase) by a maximum of approximately 80% at 2 min, (due to an increased Vmax for Na(+)-dependent glutamine transport) then decayed to a new elevated steady state after 30 min exposure. 5. During hyperosmotic (430 mosmol kg-1) exposure there were rapid decreases in glutamine transport and myotube cell volume (both by approximately 30%) to values which were maintained for at least 15 min. 6. The volume-sensitive glutamine transport process features characteristics of the insulin-sensitive system Nm transporter. 7. Modulation of Na(+)-dependent glutamine transport by insulin and cell volume changes may contribute towards regulation of muscle metabolism.

A role for membrane transport in modulation of intramuscular free glutamine turnover in streptozotocin diabetic rats

We wished to examine the effects of diabetes on muscle glutamine kinetics. Accordingly, female Wistar rats (200 g) were made diabetic by a single injection of streptozotocin (85 mg/kg) and studied 4 days later; control rats received saline. In diabetic rats, glutamine concentration of gastrocnemius muscle was 33% less than in control rats: 2.60 +/- 0.06 mumol/g vs. 3.84 +/- 0.13 mumol/g (P < 0.001). In gastrocnemius muscle, glutamine synthetase activity (Vmax) was unaltered by diabetes (approx. 235 nmol/min per g) but glutaminase Vmax increased from 146 +/- 29 to 401 +/- 94 nmol/min per g; substrate Km values of neither enzyme were affected by diabetes. Net glutamine efflux (A-V concentration difference x blood flow) from hindlimbs of diabetic rats in vivo was greater than control values (-30.0 +/- 3.2 vs. -1.9 +/- 2.6 nmol/min per g (P < 0.001)) and hindlimb NH3 uptake was concomitantly greater (about 27 nmol/min per g). The glutamine transport capacity (Vmax) of the Na-dependent System Nm in perfused hindlimb muscle was 29% lower in diabetic rats than in controls (820 +/- 50 vs. 1160 +/- 80 nmol/min per g (P < 0.01)), but transporter Km was the same in both groups (9.2 +/- 0.5 mM). The difference between inward and net glutamine fluxes indicated that glutamine efflux in perfused hindlimbs was stimulated in diabetes at physiological perfusate glutamine (0.5 mM); ammonia (1 mM in perfusate) had little effect on net glutamine flux in control and diabetic muscles. Intramuscular Na+ was 26% greater in diabetic (13.2 mumol/g) than control muscle, but muscle K+ (100 mumol/g) was similar. The accelerated rate of glutamine release from skeletal muscle and the lower muscle free glutamine concentration observed in diabetes may result from a combination of: (i), a diminished Na+ electrochemical gradient (i.e., the net driving force for glutamine accrual in muscle falls); (ii), a faster turnover of glutamine in muscle and (iii), an increased Vmax/Km for sarcolemmal glutamine efflux.

Studies of glutamine uptake across human skeletal sarcolemma

In the human body skeletal muscle is the largest store of glutamine, an important amino-acid in whole body nitrogen balance. Glutamine transport was measured in purified human skeletal muscle sarcolemmal vesicles (HMSV). The activity of sarcolemmal marker enzymes (K(+)-stimulated nitrophenylphosphatate (KpNPPase) and 5'-nucleotidase) was increased approximately 14-fold in the sarcolemmal fraction (SF) compared to the crude muscle homogenate (CH). Glutamine transport in HMSV was Na(+)-dependent (initial rate of 1 muM glutamine in the presence of 0.1 M NaCl = 7 (+/- 1.7) x 10(-3) pmol.mg(-1) protein.s(-1) compared to 1.5 (+/- 0.3) x 10(-3) pmol mg(-1) protein.s(-1) in the presence of 0.1 M Choline Cl). The rate of glutamine uptake into HMSV was increased in the presence of an inside negative membrane potential.

Effects of phenylarsine oxide on insulin-stimulated system A amino acid uptake in skeletal muscle

The role of vicinal sulfhydryls in the stimulation by insulin of system A amino acid uptake in mammalian skeletal muscle was investigated. Neutral amino acid uptake via system A carriers was assessed using the nonmetabolizable analogue alpha-(methylamino)isobutyric acid (MeAIB). Phenylarsine oxide (PAO), a trivalent arsenical that interacts with vicinal sulfhydryls, at 40 microM inhibited basal and insulin-stimulated (2 mU/ml) MeAIB uptake in rat epitrochlearis muscles by approximately 50% and approximately 80%, respectively. No significant changes in the ATP level or in the lactate-to-pyruvate ratio were observed. Both inhibitory effects were completely preventable by coincubation with dimercaptopropanol, a vicinal dithiol, indicating the effects were mediated specifically by interactions with vicinal sulfhydryls. Stimulation of MeAIB uptake by the insulin-mimicker vanadate (10 mM) or by insulin-like growth factor I (IGF-I, 20 nM) was also inhibited by 80-90% by PAO. Kinetic analysis showed that PAO decreased the apparent Vmax for basal and insulin-stimulated MeAIB uptake without altering the apparent Km. MeAIB uptake already maximally stimulated by insulin was rapidly (half-time = approximately 10 min) reversed by the addition of PAO so that the rate of MeAIB uptake was the same as in muscles incubated throughout with insulin and PAO. These results implicate a major role for vicinal sulfhydryls in the stimulation by insulin of amino acid uptake via system A carriers in skeletal muscle and suggest that the site of action of PAO on this system is distal to the insulin receptor, possibly at the carrier molecule itself.